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ABSTRACT 
Macrophages and microglia play a key role in the maintenance of nervous system homeostasis. 
However, upon different challenges, they can adopt several phenotypes, which may lead to 
divergent effects on tissue repair. After spinal cord injury (SCI), microglia and macrophages show 
predominantly pro-inflammatory activation and contribute to tissue damage. However, the factors 
that hamper their conversion to an anti-inflammatory state after SCI, or to other protective 
phenotypes, are poorly understood. Here, we show that IL-4 protein levels are undetectable in the 
spinal cord after contusion injury, which likely favors microglia and macrophages to remain in a 
pro-inflammatory state. We also demonstrate that a single delayed intraspinal injection of IL-4, 48 
hours after SCI, induces increased expression of M2 marker in microglia and macrophages. We 
also show that delayed injection of IL-4 leads to the appearance of resolution-phase macrophages, 
and that IL-4 enhances resolution of inflammation after SCI. Interestingly, we provide clear 
evidence that delayed administration of IL-4 markedly improves functional outcomes and reduces 
tissue damage after contusion injury. It is possible that these improvements are mediated by the 
presence of macrophages with M2 markers and resolution-phase macrophages. These data suggest 
that therapies aimed at increasing IL-4 levels could be valuable for the treatment of acute SCI, for 
which there are currently no effective treatments. 
 
 
 
   
INTRODUCTION 
SCI elicits an inflammatory response that comprises mainly of microglia and peripheral blood-
derived macrophages (Alexander and Popovich 2009; David et al. 2012). These cells, which 
remain chronically in the spinal cord in humans after injury (David et al. 2012; Fleming et al. 
2006), contribute directly or indirectly to tissue damage and functional loss in SCI, as well as, in 
other central nervous system disorders. However, they can promote repair in other experimental 
paradigms (Alexander and Popovich 2009; David et al. 2012; Mills et al. 2000; Popovich and 
Longbrake 2008; Yong and Rivest 2009). These paradoxically conflicting actions of microglia and 
macrophages may depend on their activation state and the signals in the lesion milieu. In response 
to IFNγ and/or LPS, macrophages undergo “classical” M1 activation (David and Kroner 2011; 
Dey et al. 2014; Gordon and Martinez 2010). However, upon IL-4 and IL-13 stimulation, they 
acquire “alternative” M2 differentiation (David and Kroner 2011; Dey et al. 2014; Gordon and 
Martinez 2010; Mills et al. 2000; Murray et al. 2014). M1 macrophages release high levels of pro-
inflammatory cytokines and free radicals that are crucial for killing microbes and tumor cells, but 
also induce damage in healthy neighboring tissue, contributing to cell loss and pathology (David 
and Kroner 2011; Dey et al. 2014; Gordon and Martinez 2010). M2 macrophages, display anti-
inflammatory features, and are involved in parasite containment, tumor progression, as well as, in 
promoting tissue repair (David and Kroner 2011; Dey et al. 2014; Gordon and Martinez 2010). 
Recently, concerns have been raised about such classification since macrophages in tissues are 
influenced by multiple factors that can influence their polarization state (Murray et al. 2014). 
Indeed, different macrophage subsets have been identified in several pathologies, including 
Ly6Chigh and Ly6Clow monocytes (Arnold et al. 2007), tumor-associated macrophages (Noy and 
Pollard 2014) and resolution-phase macrophages (Bystrom et al. 2008), among others. However, 
the concept of a pro-inflammatory/M1-like phenotype and an anti-inflammatory/M2-like 
phenotype, is a useful tool to probe for responses to injury (Murray et al. 2014).    
Microglia and macrophages display a predominantly pro-inflammatory/M1-like phenotype after 
SCI (Kigerl et al. 2009; Kroner et al. 2014). However, there is currently limited information about 
the factors that prevent these cells from acquiring a pro-repair M2-like phenotype after SCI. This 
is likely related to the post-injury milieu of the spinal cord, since M2 macrophages rapidly lose 
such markers when transplanted into the contused spinal cord (Kigerl et al. 2009). A recent report 
reveals that phagocytosis of erythrocytes, which occurs between day 7 and 14 after SCI, prevents 
macrophages to adopt a pro-repair/M2-like polarization via release of TNFα (Kroner et al. 2014). 
There is also evidence that TNFα can prevent the myelin phagocytosis-induced shift of M1 
macrophages to M2 (Kroner et al. 2014). However, the existance of mechanisms occuring at early 
stages after SCI that may hamper the convertion of microglia and macrophages from pro-
inflammatory towards a phenotype that is more conducive for tissue repair has yet to be elucidated. 
Moreover,  it is also not known whether effective induction of such phenotype in microglia and 
macrophages in the injured spinal cord attenuates functional deficits and tissue damage. Answers 
to these questions are highly relevant to advancing therapeutics to treat SCI in humans. 
In the present work, we demonstrate that IL-4 protein levels are undetected after SCI. We reveal 
that a single administration of IL-4 delayed 48h after injury is sufficient to induce the expression 
of M2 markers in microglia and macrophages, as well as, to promote the appearance of a 
macrophage subset that has a phenotype compatible with resolution-phase macrophages. Finally, 
we show that such changes in microglia and macrophage phenotype triggered by delayed IL-4 
treatment is associated with improved tissue protection and functional recovery. 
 
MATERIALS AND METHODS 
All the experimental procedures were approved by the Universitat Autònoma de Barcelona Animal 
Experimentation Ethical Committee (CEEAH 1188R3-DMAH 6131) and followed the European 
Communities Council Directive 2010/63/EU, and the methods for each procedure were carried out 
in accordance with the approved guidelines.  
Surgical procedure 
Adult (8-10 weeks old) female C57Bl/6 mice (Charles River) were anesthetized with ketamine (90 
mg/kg, i.m.) and xylazine (10 mg/kg, i.m.). After performing a laminectomy at the 11th thoracic 
vertebrae, the exposed spinal cord was contused with a force of 50 kdynes using the Infinite 
Horizon Impactor device (Precision Scientific Instrumentation) (Klopstein et al. 2012). 15 minutes 
or 48 hours after SCI, 1μl of saline or saline containing 100 ng of recombinant mouse IL-4 
(eBioscience) was injected into the injured spinal cord at the lesion site by means of a glass 
micropipette (30 µm internal diameter, Eppendorf, Hamburg, Germany) coupled to a 10 ml 
Hamilton syringe (Hamilton #701, Hamilton Co, Reno, NV, USA). 100ng of IL-4 was chosen 
based on a recent report from our laboratory using another anti-inflammatory cytokine (Coll-Miro 
et al. 2016). Injections were made at a perfusion speed of 2 µl/min controlled by an automatic 
injector (KDS 310 Plus, Kd Scientific, Holliston, MA, USA), and the tip of the needle was 
maintained inside the cord tissue 3 min after each injection to avoid liquid reflux. 
Cytokine Protein Expression 
Adult female C57/Bl6 mice were perfused with sterile saline and a 5 mm length of intact or 
contused spinal cord  was collected at 1, 6, 12 hours and at 1, 3, 7, 14 and 28 days after contusion 
(n=4 each group and time point) and snap-frozen. Spinal cords were homogenized and protein 
concentration was determined using the DC Protein Assay (Bio-Rad). Samples were concentrated 
to 4µg/µl using MicroCon centrifugation filters (Millipore) to ensure equal amounts of protein. 
Cytokine protein levels were then analyzed using the Milliplex MAP Mouse Cytokine/Chemokine 
magnetic bead panel (Millipore) on a Luminex (Millipore) as per manufacturers’ protocol. 
Flow Cytometry 
Immune cells from the injured spinal cord were analyzed by flow cytometry. Briefly, spinal cords 
were cut in little pieces and mechanically dissociated through a cell strainer of 70 µm (BD falcon) 
and the cell suspension was centrifuged twice at 300g for 10 minutes at 4ºC. Cell suspension from 
each sample was divided in 6 tubes, and each of them was incubated with combination of different 
antibodies. The following rat conjugated antibodies were used: CD45-PerCP (1:150 eBioscience), 
CD11b-PE-cy7 (1:150 eBioscience), Ly6G-PE (1:150 eBicoscience), F4/80-APC or PE,  (1:150 
eBioscience), CD16/32-PE (1:100 eBioscience) CD206-FITC (1:100 eBioscience), IL-4Rα-APC 
(1:100 Miltenyi Biotec) MHC-II (1:100 eBioscience), CD11c (1:100 eBioscience), TGFβ1-
Alexa647 (1:100 Abcam), IL-10-Alexa488 (1:100 eBioscience) and unconjugated rabbit 
antibodies against  15-LOX (1:100 Bioss Biotechnology), COX-2 (1:100 Cayman Chemical), 
iNOS (1:100 Abcam) and  goat antibodies against Arg1 (1:100 Santa Cruz). After 30 min of 
incubation with combinations of antibodies at 4°C cell were then fixed in 1% paraformaldehyde. 
For intracellular staining, cells were permeabilized with Permeabilization Wash Buffer 
(Invitrogen) and followed by staining with Alexa488 or Alexa647 conjugated donkey secondary 
antibodies against rabbit or goat (1:500 Molecular Probes) for 30 min when needed. When 
intracellular cytokine staining was performed, cells were incubated with brefeldin (1:1000, 
Biolegend) at 37º for 4 hours before the incubation with the antibodies against cytokines. Cells 
were analyzed on a FACSCanto flow cytometer (BD Biosciences) and results analyzed using 
FlowJo® software version 10.0.7.  
To perform the analysis, cells were first gated for CD45 to ensure that only infiltrating leukocytes 
and resident microglia are selected, and then, the following combination of markers were used to 
identify microglia (CD45low, CD11b+, F4/80+), macrophages (CD45high, CD11b+, F4/80+), and 
neutrophils (CD45high, CD11b+, F4/80-, Ly6G+). Since cell-associated fluorescence varies between 
the different immune cell subsets, the cut off expression was defined based on isotype controls for 
each of the immune cell subsets and sample. The number of neutrophils in the injured spinal cord 
was estimated by counting all the CD45high, CD11b+, F4/80-, Ly6G+ cells present in one of the six 
tubes each spinal cord cell suspension was divided,  and then, multiplied 6 times. 
Functional assessment 
Locomotor recovery was evaluated at 1, 3, 5, 7, 10, 14, 21 and 28 days post-injury (dpi) in an 
open-field test using the nine-point Basso Mouse Scale (BMS), which was specifically developed 
for locomotor testing after contusion injuries in mice (Basso et al. 2006). The BMS analysis of 
hindlimb movements and coordination was performed by two independent assessors and the 
consensus score taken.  In addition, at the end of the follow up (day 28 post-injury) the highest 
locomotion speed of the mice was evaluated on a belt of a motorized treadmill.  Briefly, each 
mouse was allowed to explore the treadmill compartment, with the motor speed set to zero, for 
5min. Then speed was gradually increased from 0 up to 35 cm/s and the maximum speed at which 
each mouse performed for at least 5 seconds was recorded (Santos-Nogueira et al. 2015). 
At day 28, electrophysiological tests were used to evaluate spared motor central pathways after 
SCI. Motor evoked potentials (MEPs) were recorded from the gastrocnemius muscle (GM) with 
microneedle electrodes, in response to transcranial electrical stimulation of the motor cortex by 
single rectangular pulses of 0.1ms duration. Pulses were delivered through needle electrodes 
inserted subcutaneously, the cathode over the skull overlying the sensoriomotor cortex and the 
anode at the nose (Santos-Nogueira et al. 2015). All potentials were amplified and displayed on a 
digital oscilloscope (Tektronix 450S)   
Histology 
At 28 days post-injury mice were perfused with 4% paraformaldehyde in 0.1M-phosphate buffer 
(PB) at 12h, 3 and 28 dpi. A 5mm length of spinal cord containing the lesion site was removed, 
cryoprotected with 30% sucrose in 0.1M PB at 4ºC, and 6 series of 10µm thick section were picked 
up on glass slides. Adjacent sections on the same slide were therefore 100µm apart. For 
demyelination analyses, sections were stained with Luxol fast blue (LFB) (Sigma). After graded 
dehydration, sections were placed in a 1 mg/ml LFB solution in 95% ethanol and 0.05% acetic 
acid overnight at 37ºC. Sections were then washed in 95% ethanol and distilled water before place 
them into a solution of 0.5 mg/ml Li2CO3 in distilled water for 1 min at RT. After washes in 
distilled water, sections were dehydrated and mounted in DPX mounting media (Sigma-Aldrich). 
For neuronal assessment, sections were incubated overnight at 4ºC with biotinilated antibodies 
against NeuN (1:500; Millipore). After several washes in PBS, sections were incubated with Alexa 
594-conjugated streptoavidin, and then coverslipped in Mowiol mounting media (Sigma-Aldrich). 
The epicenter of the injection or contusion injury impact was determined for each mouse spinal 
cord by localizing the tissue section with the greatest damage using LFB stained section. Myelin 
sparing after SCI was calculated by delineating the spared LFB stained tissue, whereas neuronal 
survival was assessed by counting the number of NeuN+ cells in the ventral horns at the injury 
epicenter and at rostral and caudal areas. The NIH ImageJ software was used to quantify all the 
histological parameters. 
 
Statistical analysis 
All analyses were conducted with SPSS version19. Changes in the expression of M1 and M2 
markers after spinal cord were analyzed by using one-way ANOVA with Tukey post-hoc 
comparisons. Functional follow-up for BMS score and subscore, histological analysis of myelin 
and neuronal sparing were analyzed using two-way repeated measure ANOVA with Bonferroni’s 
correction for multiple comparison. Student t-test was used for single comparisons between two 
groups. Results are expressed as mean ± SEM. Differences were considered significant at p < 0.05. 
 
RESULTS 
Microglia and macrophages do not acquire anti-inflammatory phenotype after SCI 
Previous reports describe that microglia and macrophages express predominantly M1 markers for 
the first 2 weeks after SCI, whereas the expression of M2 signatures is scarce (Kigerl et al. 2009; 
Kroner et al. 2014). Here we first extended these observations using fluorescence-activated cell 
sorting analysis (FACS) to assess the temporal changes in expression of M1 (iNOS and CD16/32) 
and M2 (Arg1 and CD206) markers in microglia and macrophages for the first 4 weeks after spinal 
cord contusion injury in mice. We confirmed that these cells express mainly M1 markers after SCI, 
whereas the expression of M2 markers is restricted to a small population of microglia and 
macrophages (Fig. 1A-E). However, the expression of the M1 markers did not show a similar 
pattern. Most microglial cells and macrophages expressed CD16/32 for the entire 4 weeks period, 
however, this expression was more pronounced in microglia than macrophages (Fig. 1E). The 
expression of iNOS, which was scarcely detected in microglial cells from uninjured spinal cords 
(~15%), was induced in ~70% of microglia and found in ~55% of macrophages for the first 3 days 
post-injury. However, we found that iNOS levels markedly dropped in microglia at day 28, when 
it reached basal levels, but also, although to lesser extent, in macrophages (Fig. 1E).  
These results suggest that microglia and macrophage express predominantly M1 markers during 
the first days after SCI, and fail to adopt an M2-like phenotype. 
The lack of IL-4 expression in the injured spinal cord favors pro-inflammatory activation of 
microglia and macrophages  
Since cytokines are one of main factors that regulate the functional phenotype of microglia and 
macrophage in vitro (Boche et al. 2013; David and Kroner 2011; Mantovani et al. 2013), we 
monitored the expression of the main cytokines in the spinal cord tissue following contusion lesion. 
We found that protein levels for most pro-inflammatory cytokines peaked between 6-12 hours 
post-injury (Fig. 2). The reduction of cytokines was already evident at 24 hours post-injury, and 
most of them reached basal levels at day 3. A small number of cytokines, however, remained 
elevated up to day 28, although to much lower levels as compared to the first 12 hours post-injury 
(Fig. 2). Interestingly, the protein levels of IL-4, one of the main M2 inducers, was undetected at 
any time point (Fig. 2), which led us to hypothesize that the insufficient expression of IL-4 after 
SCI could account for the deficit of microglia and macrophages to adopt an M2-like phenotype.  
To address this hypothesis, we first characterized the expression of IL-4Rα in the spinal cord by 
FACS analysis. We found that IL-4Rα was not expressed in the uninjured spinal cord spinal but 
was found after contusion injury (Fig. 3A). Interestingly, we observed that ~90% of the IL-4Rα+ 
cells are also CD45+, indicating the presence of this receptor is mainly restricted to microglia and 
infiltrating myeloid cells in the injured spinal cord. We then studied whether IL-4Rα was present 
in microglia and macrophages based on CD45, CD11b and F4/80 expression. Although microglia 
did not show constitutive expression of IL-4Rα, it was induced in ~55 % of microglia at 18 hours 
after injury, remaining at steady levels at day 2 (Fig. 3B). In addition, peripheral macrophages, 
which migrate into the spinal cord after injury, showed similar proportion of IL-4Rα at the same 
time points (Fig. 3B).  
Since IL-R4α was found in microglia and macrophages only after SCI, we then assessed the effects 
of increased levels of IL-4 in the contused spinal cord parenchyma, by injecting recombinant 
mouse IL-4 into the spinal cord, 15 minutes after contusion injury in adult mice. We observed that 
IL-4 induced the expression of Arg1 in ~30% of microglia and macrophages at day 3, but failed 
to modulate the levels of CD206 (Fig. 4, Fig. 5A). IL-4, however, did not reduce CD16/32 and 
iNOS expression in these cells (Fig. 4, Fig. 5A).  This data shows that a single acute administration 
of IL-4 after SCI drives some aspects of M2 polarization in a small proportion of microglia and 
macrophages, suggesting that the insufficient levels of this cytokine in the contused spinal cord 
contributes to hamper the conversion of microglia and macrophages towards a more pro-repair 
phenotype after SCI.   
Effects of delayed administration of IL-4 on microglia and macrophage phenotype  
We hypothesized that the high levels of pro-inflammatory cytokines in the contused spinal cord 
within the first 6-12 hours, some of them being well known M1 inducers, together with the absence 
of IL-4R in the intact spinal cord, may have minimized the effects of acute administration of IL-4 
(15 minutes after SCI) on the phenotype of microglia and macrophages. We therefore evaluated 
whether delaying the administration of IL-4 to 48 hours post-injury, when levels of most pro-
inflammatory cytokines have markedly dropped and the expression of IL-4R is found in ~55% of 
microglia and macrophages (Fig. 3B), would be more effective in inducing an anti-
inflammatory/pro-repair phenotype.  In contrast to Arg-1, being expressed in ~30% of microglia 
and macrophages after acute injection (15 minutes post-SCI), delaying the injection of IL-4 to 48 
hours post-SCI, increased Arg-1 expression in ~55% macrophages and in about 35% of microglia 
(Fig. 5B; Fig. S1). Moreover, in contrast to acute injection, delayed IL-4-administration also 
induced the expression of the M2 marker CD206 in microglia and macrophages (~25%) (Fig. 5B), 
indicating that delayed IL-4 treatment leads to rapid and more effective induction of M2 markers 
in a subset of microglia and macrophages in the injured spinal cord.  
We also found that the expression of CD16/32 is increased slightly in microglia and macrophages 
after delayed injection of IL-4, whereas the expression of iNOS remained unaltered (Fig. 5B, Fig. 
S1).  
Given previous reports showing that M2 macrophages lose Arg1 expression within 3 days after 
their transplantation into the injured spinal cord (Kigerl et al. 2009; Kroner et al. 2014), we 
assessed whether the responses of microglia and macrophages to delayed administration of IL-4 
were acute or persisted for a few days. We found that 4 days post-injection (i.e., 6 days after SCI), 
the expression of Arg1 and CD206 in microglia and macrophages remained at similar levels as 
compared to day 1 post-injection (Fig. 5C, Fig. S2), indicating that the expression of M2 markers 
is maintained for up to 4 days. The expression of CD16/32 in microglia and macrophages, which 
was increased at day 1 post-delayed injection, was reduced back down to saline-injected mice, 
whereas the expression of iNOS was significantly reduced in both immune cell populations at 4 
days after IL-4 injection (Fig. 5C, Fig S2). These results therefore suggest that microglia and 
macrophages are more skewed toward anti-inflammatory/M2-like activation over time after a 
single delayed injection of IL-4.   
Delayed administration of IL-4 induces the appearance of resolution-phase macrophages 
Spinal cords that received a delayed injection of IL-4 and taken 6 days post-injury for flow 
cytometry analysis of CD11b and CD45 showed  the 2 expected populations of macrophages 
(CD11b+, CD45high) and microglia (CD11b+, CD45low) (Fig 6A). Strikingly, the IL-4 treated 
spinal cord also showed another cell population that has higher levels of CD45 and lower levels 
of CD11b as compared to the infiltrating macrophage population. On further characterization of 
this immune cell subset we found that they expressed F4/80 and MHCII, but did not display 
CD11c, suggesting they were macrophages (Fig. 6B). Moreover, they expressed iNOS, CD16/32, 
CD206 and Arg1, indicative of a mixed M1/M2 phenotype (Fig. 6B). A variant activated form of 
macrophage was reported recently in the resolution phase of inflammation elicited by 
intraperitoneal administration of zymozan (Bystrom et al. 2008; Stables et al. 2011). These 
macrophages, referred to as "resolution-phase" macrophages express a mixed M1/M2 phenotype 
(expressing MHCII but lacking CD11c expression) (Bystrom et al. 2008; Li et al. 2013; Stables et 
al. 2011), like the new macrophage subset we see in the spinal cord after delayed IL-4 injection. 
In addition, these cells were reported to express anti-inflammatory cytokines as well as 
lipoxygenase (LOX) and cyclooxygenase (COX-2), key enzymes in the synthesis of the 
specialized pro-resolving lipid mediators, which turn on the resolution programs of inflammation 
(Bystrom et al. 2008; Li et al. 2013; Schwab et al. 2007; Serhan 2014). We therefore assessed 
whether the new macrophage subset found after delayed IL-4 injection also displayed these 
resolution-phase markers. Interestingly, these macrophages expressed 5-LOX, 15-LOX and COX-
2 (Fig. 6B), as well as the anti-inflammatory cytokines IL10, and TGFβ1 (Fig. 6b; table 1). Note 
that  IL-4 only increased the expression of these anti-inflammatory/resolving markers in this new 
macrophage subset, but not in microglia or macrophages, with the exception for 15-LOX, which 
was increased by ~25%  in macrophages after IL-4 administration (Table 1). Therefore, these data 
indicate that delayed administration of IL-4, which modulates microglia and macrophage 
phenotype after SCI, also leads to the appearance of a macrophage subset, which phenotypically 
resembles "resolution-phase" macrophages. 
Since "resolution-phase" macrophages are important in resolving inflammation, we next 
investigated whether the delayed intraspinal injection of IL-4 enhanced the clearance of 
neutrophils from the contused spinal cord, a key step in the resolution of inflammation (Schwab et 
al. 2007; Serhan 2014). Neutrophil infiltration peaks in the contused spinal cord at day 1 after 
injury and decreases gradually in 7-10 days (David et al. 2012; Stirling and Yong 2008), which 
allowed us to assess whether their elimination was speeded by delayed administration of IL-4. 
Interestingly, we found that IL-4 injection reduced the number of neutrophils (CD45high, CD11b+, 
F4/80-, Ly6G+) by ~40%  in the injured spinal cord at 6 days post-injury (i.e. 4 days post-injection) 
(Fig. 6c), supporting the idea that the resolution of inflammation is enhanced by IL-4. 
Effects of delayed administration of IL-4 on functional and histopathological outcomes after 
SCI 
We finally assessed whether delayed administration of IL-4 also led to functional recovery and 
reduced tissue damage after SCI. We found that delayed IL-4 treatment conferred significant 
protection against loss of locomotor function after SCI based the on the BMS scale (Fig. 7A,B). 
At day 28 post-injury (the latest time point examined), 90% of saline-injected (control) mice 
showed plantar placement of the hindlimbs and only 40% displayed occasional stepping. However, 
all the IL-4-injected mice showed plantar placement and 83% of them showed occasional or 
frequent plantar stepping. In addition, mice treated with IL-4 were able to perform faster 
locomotion on the treadmill (Fig. 7C). Additionally, electrophysiological evaluation of motor 
evoked potentials revealed that IL-4 treatment led to ~2.5-fold greater preservation of central 
descending axonal pathways, and conduction was slightly but significantly faster (Fig. 7D-E), 
indicating that delayed IL-4 administration led to greater integrity of spinal motor pathways.  
In line with the functional data, histopathological analysis revealed that IL-4 treatment led to 
significant enhancement in myelin sparing at the injury epicenter and in adjacent areas (Fig. 7F-
G), as well as, greater preservation of neurons but only at caudal regions to the injury epicenter 
(Fig. 7H-I). Overall, this data provides clear evidence that delayed administration of IL-4 enhances 
functional and histological outcomes after SCI. 
 
DISCUSSION 
At present, there is no effective treatment for acute SCI, however, a large body of experimental 
reports reveal that inflammation exacerbates tissue damage and functional loss after SCI (David 
et al. 2012; Hawthorne and Popovich 2011; Ren and Young 2013). This is due, in part, to the 
release of numerous mediators from microglia and macrophages that exert cytotoxic effects on 
CNS cells that can lead to demyelination and neuronal loss (David et al. 2012; Hawthorne and 
Popovich 2011; Ren and Young 2013). Nevertheless, these cells also produce a variety of factors 
that promote cell survival and tissue healing, and under certain circumstances, may lead to 
protective effects in the injured CNS (David et al. 2012; Popovich and Longbrake 2008).  These 
conflicting actions of microglia and macrophages are due to the plasticity of these cells that 
depends on factors in the immediate environment. Thus, understanding the mechanisms that drive 
microglia and macrophage activation toward a phenotype that is conducive for tissue repair can 
lead to therapies that are more effective to treat acute SCI. 
In agreement with previous studies, we show here that microglia and macrophages express 
predominantly M1 markers after SCI, whereas the expression of M2 markers is restricted to a small 
subpopulation, indicating that these cells adopt predominantly a pro-inflammatory phenotype after 
SCI (Kigerl et al. 2009; Kroner et al. 2014). Our data, in agreement with previous reports, also 
highlights that microglia and macrophages after SCI cannot be defined within the simple M1-M2 
classification described for cells in culture, but fall into a spectrum of activation states depending 
the stimuli acting on these cells and the markers examined (David et al. 2015; Murray et al. 2014). 
This is reflected in our data, since the expression of the M1 markers (iNOS and CD16/32) was 
found in most microglial cells and macrophages for the first three days following injury, but the 
expression of iNOS, but not CD16/32, was progressively lost over time. Similarly, a recent study 
reports that the expression of CD86, another M1 marker, is also lost from microglia and 
macrophages over time (Kroner et al. 2014). We also observed, in agreement with a previous report 
(Kroner et al. 2014) that only a small subset of  microglia and macrophages expressed M2 markers. 
This is not surprising as microglia and macrophages in vivo in the injured spinal cord are influenced 
by a variety of both pro and anti-inflammatory stimuli (David et al. 2015). In contrast, a previous  
study showed that M2 macrophages are abundant in the spinal cord of irradiated mice at 2 weeks 
post-injury,  and reach the injury site through the choroid plexus migrating along the central canal 
(Shechter and Schwartz 2013). However, these M2 macrophages were classified based on the lack 
of Ly6C expression and not to the presence of classical M2 markers. This may account for the 
difference in interpretation of how many M2 cells are present after SCI between this study and our 
data. However, the majority of the evidence in the literature suggests that there is heterogeneity in 
microglia/macrophage phenotypes in the injured spinal cord but they are skewed mainly to a M1 
polarization state.  
Previous studies indicate that the environment of the injured spinal cord does not favor M2 
polarization (Kigerl et al. 2009; Kroner et al. 2014) as M2 macrophages obtained from cell culture 
rapidly lose Arg1 expression when transplanted into the injured spinal cord (Kigerl et al. 2009). 
Polarization of microglia/macrophages into M1/M2 in vitro is induced upon stimulation with 
different cytokines (Mills et al. 2000; Murray et al. 2014; Sica and Mantovani 2012).  Therefore, 
it is likely that the functional phenotype of microglia and macrophages after SCI might  depend on 
the balance between the levels of  pro-inflammatory M1 and anti-inflammatory M2 cytokines 
found in the injured spinal cord environment (David et al. 2015).  Our analysis of cytokine 
expression shows that most pro-inflammatory cytokines are increased at the protein levels in the 
spinal cord for the first 24 hours post-injury, and most of them dropped to basal levels by day 3. 
This pattern of changes is also seen at the mRNA level (Pineau and Lacroix 2007).  Interestingly, 
the expression of cytokines that induce distinct alternative activation of macrophages was either 
undetectable (i.e. IL-4) or expressed at low levels and only for the first 24 hours post-injury (i.e. 
IL-10 and IL-13). Although IL-4 was not detected in the contused spinal cord, it is likely to be 
present at very low levels, as a previous study reported that IL-4Rα null mice show greater 
functional deficits after SCI (Fenn et al. 2014). In the current work, however, we found that 
increasing the levels of IL-4 in the injured spinal cord by direct intraspinal injection of IL-4 induces 
the expression of M2 markers in microglia and macrophages. These data suggest that the low levels 
of IL-4 in the contused spinal cord may underlie the low numbers of M2 polarized cells seen after 
SCI. Previous ex-vivo studies have shown that activated microglia from adult and aged brain can 
be redirected toward a M2-like phenotype by IL-4 (Fenn et al. 2012).Our work suggests that IL-4 
may also induce such as shift in vivo after SCI.  Additionally, our work also revealed this effect of 
IL-4 on M2 polarization is more effective when administered after a delay of 48 hours post-injury. 
This may be due to the high levels of pro-inflammatory cytokines in the spinal cord during the first 
24 hours post-injury (Pineau and Lacroix 2007) that may hamper the effectiveness of IL-4 when 
injected immediately after injury (15 minutes). Indeed, a recent work reveals that TNFα, which is 
increased in the injured spinal cord for the first 24 hours, prevents the induction of M2 markers in 
microglia and macrophages after SCI (Kroner et al. 2014), as well as in tumor macrophages 
(Kratochvill et al. 2015). It is likely that other pro-inflammatory cytokines and/or mediators 
synthesized during the first few hours post-injury could also exert a similar effect.   Our data, along 
with another report (Fenn et al. 2014), indicates that microglia do not show constitutive expression 
of IL-4Rα. This may also limit the capacity of acute IL-4 administration to induce an anti-
inflammatory phenotype. In addition, the very low levels of infiltration of blood borne monocytes 
into the spinal cord during the first 24 hours post-injury may also explain the low effectiveness of 
acute IL-4 to induce M2 markers in this immune cell population.  However, at 48 hours post-
injury, IL-4R is expressed on microglia, macrophage infiltration is abundant, and the levels of 
most of the pro-inflammatory cytokines are low at close to basal levels.  At this point, the 
administration of IL-4 has greater effects in counteracting the pro-inflammatory polarizing 
environment of the injured spinal cord. This approach induced ~40% of microglia and ~55% of 
macrophages to acquire M2 markers, since only ~55% of these two immune cells expressed IL-
4R at 48 hours post-injury. To our knowledge, this is currently the most effective strategy in 
inducing M2 markers in microglia and macrophages after SCI.  
In many tissues, a switch in macrophage phenotype accompanies the resolution of inflammation. 
Transcriptomic profiling of isolated resolution-phase macrophages reveal that they show a mixed 
M1/M2 phenotype (Bystrom et al. 2008). Resolution-phase macrophages are enriched with MHCII 
expression and lack CD11c (Stables et al. 2011). They also express anti-inflammatory cytokines, 
such as TGFβ1 and IL-10 (Li et al. 2013; Stables et al. 2011). Importantly, they have elevated 
expression of COX-2 and LOX (Li et al. 2013; Stables et al. 2011), key enzymes in the synthesis 
of specialized pro-resolving mediators that actively turn off inflammation (Schwab et al. 2007; 
Serhan 2014).   Our data reveal that only a small proportion of macrophages display M2 markers, 
suggesting that resolution-phase macrophages are scarce in SCI, which may explain, in part, why 
inflammation remains active for several months or even years in this pathology.  However, we 
found that delayed IL-4 treatment induced the appearance of a new immune cell subset in the 
spinal cord. Further characterization of this immune cell subset revealed that they were 
macrophages with a phenotype similar to resolution-phase macrophages (5-LOX, 15-LOX, COX-
2, TGF1, IL-10). Whether this is due to either direct or indirect effects of IL-4 on macrophages 
is not known.  In line with these results, we also found that the clearance of neutrophils from the 
injured spinal cord, which is a key step in the resolution of inflammation (Li et al. 2013; Schwab 
et al. 2007; Serhan 2014), was markedly accelerated after delayed IL-4 injection, linking the lack 
of IL-4 with a deficit in resolution of inflammation after SCI. 
Delayed administration of IL-4 not only modulated microglia and macrophage phenotype after 
SCI, but more importantly, was accompanied by a substantial reduction in tissue damage and 
functional deficits, assessed by a variety of functional, electrophysiological and histopathological 
analysis. Since IL-4Rα was mainly found in microglia and macrophages, our results indicate that 
the effects of delayed administration of IL-4 on microglia and macrophage exerted restorative 
effects after SCI.  
Taken together, our data reveals that the insufficient induction of IL-4 after SCI is responsible, in 
part, to drive microglia and macrophages towards a phenotype that is not conducive to tissue repair 
and functional recovery. We show that a single, delayed injection of IL-4 induces the appearance 
of a resolution-phase macrophage subpopulation and increased numbers of M2 macrophages in 
the injured spinal cord.  Delayed IL-4 injection also reduced tissue damage and locomotor 
impairment after SCI. As IL-4 is undetected in human CSF samples after acute SCI (Kwon et al. 
2010), these findings may also be of relevance to SCI in humans. Therefore, therapies that increase 
IL-4 levels in the injured spinal cord could be a good approach with a wide therapeutic window 
for the treatment of acute SCI. 
 
 
ACKNOWLEDGEMENTS  
The authors declare no competing financial interests. Authors thank Marta Morell and Jessica 
Jaramillo for technical assistance. This work was supported by grants from the Spanish Ministry 
of Economy and Competitiveness (SAF2013-48431-R), International Foundation for Research in 
Paraplegia and by funds from the Fondo de Investigación Sanitaria of Spain (TERCEL and 
CIBERNED) to R.L-V.   
 
  
REFERENCES  
Alexander JK, Popovich PG. 2009. Neuroinflammation in spinal cord injury: therapeutic targets 
for neuroprotection and regeneration. Prog Brain Res 175:125-37. 
Arnold L, Henry A, Poron F, Baba-Amer Y, van Rooijen N, Plonquet A, Gherardi RK, Chazaud 
B. 2007. Inflammatory monocytes recruited after skeletal muscle injury switch into 
antiinflammatory macrophages to support myogenesis. J Exp Med 204:1057-69. 
Basso DM, Fisher LC, Anderson AJ, Jakeman LB, McTigue DM, Popovich PG. 2006. Basso 
Mouse Scale for locomotion detects differences in recovery after spinal cord injury in five 
common mouse strains. J Neurotrauma 23:635-59. 
Boche D, Perry VH, Nicoll JA. 2013. Review: activation patterns of microglia and their 
identification in the human brain. Neuropathol Appl Neurobiol 39:3-18. 
Bystrom J, Evans I, Newson J, Stables M, Toor I, van Rooijen N, Crawford M, Colville-Nash P, 
Farrow S, Gilroy DW. 2008. Resolution-phase macrophages possess a unique 
inflammatory phenotype that is controlled by cAMP. Blood 112:4117-27. 
Coll-Miro M, Francos-Quijorna I, Santos-Nogueira E, Torres-Espin A, Bufler P, Dinarello CA, 
Lopez-Vales R. 2016. Beneficial effects of IL-37 after spinal cord injury in mice. Proc Natl 
Acad Sci U S A 113:1411-6. 
David S, Greenhalgh AD, Kroner A. 2015. Macrophage and microglial plasticity in the injured 
spinal cord. Neuroscience 307:311-8. 
David S, Kroner A. 2011. Repertoire of microglial and macrophage responses after spinal cord 
injury. Nature reviews Neuroscience 12:388-99. 
David S, Lopez-Vales R, Wee Yong V. 2012. Harmful and beneficial effects of inflammation after 
spinal cord injury: potential therapeutic implications. Handb Clin Neurol 109:485-502. 
Dey A, Allen J, Hankey-Giblin PA. 2014. Ontogeny and polarization of macrophages in 
inflammation: blood monocytes versus tissue macrophages. Front Immunol 5:683. 
Fenn AM, Hall JC, Gensel JC, Popovich PG, Godbout JP. 2014. IL-4 signaling drives a unique 
arginase+/IL-1beta+ microglia phenotype and recruits macrophages to the inflammatory 
CNS: consequences of age-related deficits in IL-4Ralpha after traumatic spinal cord injury. 
J Neurosci 34:8904-17. 
Fenn AM, Henry CJ, Huang Y, Dugan A, Godbout JP. 2012. Lipopolysaccharide-induced 
interleukin (IL)-4 receptor-alpha expression and corresponding sensitivity to the M2 
promoting effects of IL-4 are impaired in microglia of aged mice. Brain Behav Immun 
26:766-77. 
Fleming JC, Norenberg MD, Ramsay DA, Dekaban GA, Marcillo AE, Saenz AD, Pasquale-Styles 
M, Dietrich WD, Weaver LC. 2006. The cellular inflammatory response in human spinal 
cords after injury. Brain 129:3249-69. 
Gordon S, Martinez FO. 2010. Alternative activation of macrophages: mechanism and functions. 
Immunity 32:593-604. 
Hawthorne AL, Popovich PG. 2011. Emerging concepts in myeloid cell biology after spinal cord 
injury. Neurotherapeutics 8:252-61. 
Kigerl KA, Gensel JC, Ankeny DP, Alexander JK, Donnelly DJ, Popovich PG. 2009. 
Identification of two distinct macrophage subsets with divergent effects causing either 
neurotoxicity or regeneration in the injured mouse spinal cord. The Journal of neuroscience 
: the official journal of the Society for Neuroscience 29:13435-44. 
Klopstein A, Santos-Nogueira E, Francos-Quijorna I, Redensek A, David S, Navarro X, Lopez-
Vales R. 2012. Beneficial effects of alphaB-crystallin in spinal cord contusion injury. The 
Journal of neuroscience : the official journal of the Society for Neuroscience 32:14478-88. 
Kratochvill F, Neale G, Haverkamp JM, Van de Velde LA, Smith AM, Kawauchi D, McEvoy J, 
Roussel MF, Dyer MA, Qualls JE and others. 2015. TNF Counterbalances the Emergence 
of M2 Tumor Macrophages. Cell Rep 12:1902-14. 
Kroner A, Greenhalgh AD, Zarruk JG, Passos Dos Santos R, Gaestel M, David S. 2014. TNF and 
increased intracellular iron alter macrophage polarization to a detrimental M1 phenotype 
in the injured spinal cord. Neuron 83:1098-116. 
Kwon BK, Stammers AM, Belanger LM, Bernardo A, Chan D, Bishop CM, Slobogean GP, Zhang 
H, Umedaly H, Giffin M and others. 2010. Cerebrospinal fluid inflammatory cytokines and 
biomarkers of injury severity in acute human spinal cord injury. J Neurotrauma 27:669-82. 
Li Y, Dalli J, Chiang N, Baron RM, Quintana C, Serhan CN. 2013. Plasticity of leukocytic 
exudates in resolving acute inflammation is regulated by MicroRNA and proresolving 
mediators. Immunity 39:885-98. 
Mantovani A, Biswas SK, Galdiero MR, Sica A, Locati M. 2013. Macrophage plasticity and 
polarization in tissue repair and remodelling. J Pathol 229:176-85. 
Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. 2000. M-1/M-2 macrophages and the 
Th1/Th2 paradigm. Journal of Immunology 164:6166-6173. 
Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, Gordon S, Hamilton JA, 
Ivashkiv LB, Lawrence T and others. 2014. Macrophage activation and polarization: 
nomenclature and experimental guidelines. Immunity 41:14-20. 
Noy R, Pollard JW. 2014. Tumor-associated macrophages: from mechanisms to therapy. Immunity 
41:49-61. 
Pineau I, Lacroix S. 2007. Proinflammatory cytokine synthesis in the injured mouse spinal cord: 
multiphasic expression pattern and identification of the cell types involved. J Comp Neurol 
500:267-85. 
Popovich PG, Longbrake EE. 2008. Can the immune system be harnessed to repair the CNS? Nat 
Rev Neurosci 9:481-93. 
Ren Y, Young W. 2013. Managing inflammation after spinal cord injury through manipulation of 
macrophage function. Neural Plast 2013:945034. 
Santos-Nogueira E, Lopez-Serrano C, Hernandez J, Lago N, Astudillo AM, Balsinde J, Estivill-
Torrus G, de Fonseca FR, Chun J, Lopez-Vales R. 2015. Activation of Lysophosphatidic 
Acid Receptor Type 1 Contributes to Pathophysiology of Spinal Cord Injury. J Neurosci 
35:10224-35. 
Schwab JM, Chiang N, Arita M, Serhan CN. 2007. Resolvin E1 and protectin D1 activate 
inflammation-resolution programmes. Nature 447:869-74. 
Serhan CN. 2014. Pro-resolving lipid mediators are leads for resolution physiology. Nature 
510:92-101. 
Shechter R, Schwartz M. 2013. Harnessing monocyte-derived macrophages to control central 
nervous system pathologies: no longer 'if' but 'how'. J Pathol 229:332-46. 
Sica A, Mantovani A. 2012. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 
122:787-95. 
Stables MJ, Shah S, Camon EB, Lovering RC, Newson J, Bystrom J, Farrow S, Gilroy DW. 2011. 
Transcriptomic analyses of murine resolution-phase macrophages. Blood 118:e192-208. 
Stirling DP, Yong VW. 2008. Dynamics of the inflammatory response after murine spinal cord 
injury revealed by flow cytometry. Journal of neuroscience research 86:1944-58. 
Yong VW, Rivest S. 2009. Taking advantage of the systemic immune system to cure brain 
diseases. Neuron 64:55-60. 
 
  
FIGURE LEGENDS 
Figure 1. Microglia and macrophages show predominant expression of M1 markers after 
SCI. (A) Representative FACS dot plots of injured spinal cord showing how microglia and 
macrophages were gated. Note the CD45+ cells (panel I) were further gated in CD11b+ expression 
to distinguish between microglia (CD45low CD11b+) and myeloid cells (CD45high CD11b+) (panel 
II). Myeloid cells were further differentiated based on F4/80 expression to identify macrophages 
(F4/80+) (panel III).  (B-D) Representative FACS histograms plots of M1 and M2 markers in 
uninjured spinal cord for microglia (B) and of microglia (C) and macrophages (D) at 3 days after 
SCI. These plots show the labelling for different M1 and M2 markers, as well as, for their 
respective isotype controls. (E) Graphs showing the quantification of microglia and macrophages 
expressing M1 and M2 markers after SCI. Note the percentage of microglia and macrophages 
expressing M1 markers (CD16/32 and iNOS) is markedly higher as compared to the scarce 
expression of M2 markers (Arg1 and CD206). Mean ± SEM. (n=4 per group). *p<0.05 compared 
to microglia from uninjured spinal cord; # p<0.05 compared to day 1 post-injury; + p<0.05 
compared to microglia at the same day post-injury. One-way ANOVA with Bonferroni’s post hoc 
correction was performed for the analysis. 
 
Figure 2. Dynamic changes in cytokine levels in the spinal cord after contusion injury. Heat 
map showing the changes in protein levels of relevant pro-inflammatory cytokines and anti-
inflammatory in the injured spinal cord obtained by doing Luminex analysis. Mean ± SEM. (n=4 
per time point).  
 
Figure 3. Expression of IL-4Rα after SCI. (A) Flow cytometry plots of showing the cut off of 
the isotype control (panel I), and the expression of IL-4Rα in the uninjured spinal cord (panel II), 
and at 18 post-injury (panel iii). Note that IL-4Rα is lacking in the uninjured spinal cord but it is 
rapidly detected after spinal cord injury, mostly in CD45+ cells (panel IV). (B) FACS plot 
histogram gated on the microglia and macrophage population (as shown in Fig. 1a) of intact and 
injured spinal cord at 18 hours and 48 hours post-injury. Note that IL-4Rα is not constitutively 
expressed in microglia, but it is found in >50% of microglia cells and infiltrated macrophages after 
SCI. Mean ± SEM (n=4 per time point).  
 
Figure 4. Acute administration of IL-4 induces Arg1 expression in microglia and 
macrophages at day 3 after SCI. (A) Flow cytometry density plots showing the effects of acute 
intraspinal injection of IL-4 in the expression of M1 markers (iNOS and CD16/32) and M2 markers 
(Arg1 and CD206) in microglia and macrophages at day 3 after SCI. Note that IL-4 increased the 
proportion of microglia and macrophages expressing Arg1, but did not modulate the expression of 
iNOS, CD16/32 or CD206.  
Figure 5. Delayed administration of IL-4 has greater effects in inducing M2 markers in 
microglia and macrophages than acute IL-4 injection. (A-C) Graphs showing the changes in 
the expression of M1 and M2 markers in microglia and macrophages at 3 days post-injury after 
acute IL-4 injection (A) or delayed IL-4 injection (B), and at 6 days post-injury after delayed IL-
4 injection (C). Mean ±SEM. (n=4 per group) Note that microglia and macrophages adopt greater 
expression of M2 markers after delayed injection of IL-4, and the expression of M2 markers is 
maintained for at least 4 days. *p<0.05 vs saline. Student t test was used to analyze significant 
differences between IL-4 and saline injected mice.  
Figure 6. Delayed administration of IL-4 triggers the appearance of resolution-phase 
macrophages. (A) Flow cytometry density plot showing CD45+ and CD11b+ cells from 6 days 
post-injury spinal cords of mice receiving delayed injection of saline or IL-4. Note the presence of 
resolution-phase macrophages in the contused spinal cord only after delayed IL-4 administration. 
(B) Representative flow cytometry histograms characterizing the expression of resolution-phase 
macrophages. (C) Representative flow cytometry dot plots showing granulocytes in the contused 
spinal cord at 6 days post-injury. Note that neutrophil clearance is enhanced after delayed IL-4 
injection. Mean ± SEM. (n=4 per group). *p<0.05 vs saline. Student t test was used to analyze 
significant differences between IL-4 and saline injected mice.  
 
Figure 7. Delayed intraspinal injection of IL-4 reduces functional deficits and tissue damage 
after SCI. (A-B). Mice treated with of IL-4 at 48 hours post-injury showed significant 
improvement in locomotor skills using the (A) BMS score and (B) BMS subscore, as well as (C) 
faster locomotion on a treadmill. Arrows indicate the day IL-4 was injected in the spinal cord. (D-
E) Administration of IL-4 led to greater preservation of MEPS. (D) Quantification MEPs 
recordings in the gastrocnemius muscle at day 28 post-injury and (E) representative MEPs 
recordings from saline and IL-4 treated mice. (F-I) Delayed IL-4 treatment reduced secondary 
tissue damage after SCI. (F) Quantification of myelin sparing at various distances rostral and 
caudal to the injury epicenter reveals significant reduction in myelin loss at the epicenter of the 
injury and in adjacent sections in mice treated with IL-4. (G) Representative micrographs showing 
myelin sparing at the injury epicenter in section stained against LFB from mice treated with saline 
or IL-4. (H) Quantification of ventral horn neuron survival at various distances rostral and caudal 
to the injury epicenter reveals significantly greater neuronal survival in caudal regions to the injury 
epicenter in mice treated with IL-4. (I) Representative micrographs showing sparing of ventral 
horn neurons in mice administered with saline or IL-4 in sections stained against NeuN at 1000 
µm caudal to the injury epicenter.  Mean ± SEM. (n=8 per group). *p<0.05 vs saline. Note the 
greater preservation of neurons after delayed IL-4, especially, in the most ventral region (white 
arrowheads). Two-way repeated-measures ANOVA with Bonferroni’s post hoc correction was 
used to analyze significant differences between saline and delayed IL-4 injection in the BMS score 
and subscore, as well as, in histological parameters, and t-test for electrophysiological data. 
 
